HCC_Awareness_Campaign

✔️ A wonderful work in the HCC.

Fascinating panel "Gastrointestinal Cancers" has started, Dr. amir sadeghi Dr. Massoud Vosough, MD, Ph.D Dr. Babak Yadegar Dr. S Afshar ,PhD. Dr. Ali Yaghoubi Joybari Dr. Mahsa Mollapour

A new study reported the improved effectiveness of a novel #drug_delivery_system leveraging silver-doped #zinc_oxide_magnetic_nanocarrier (#ZnO_SPION_Ag_NPs) loaded with the tyrosine kinase inhibitor sorafenib against #hepatocellular_carcinoma (HCC). This innovative system aims to overcome the limitations of #sorafenib, including poor bioavailability and the associated side effects while employing green synthesis techniques for environmental benefits. The results of this study demonstrated significant improvements in #anticancer effects through gene expression modulation and improved therapeutic outcomes in #HCC rat models, suggesting a promising avenue for treating this prevalent malignancy. REF: https://lnkd.in/dg8YCk_v #HCC_Awareness_Campaign #Hepatocellular_carcinoma #Drug_delivery_system #Targeted_therapies #anticancer #sorafenib #Cancer #liver

Sonic Hedgehog (SHH) signaling is the key driver in initiation, progression, migration, and recurrence of HCC particularly in regulation of cancer stem cells. Glioma-associated oncogene (GLI) family zinc finger are key transcription factors in the development of many organs and are de-regulated in cancer. Liver cancer cells were treated with GLI-specific decoy oligodeoxynucleotide (ODN) to evaluate the anticancer impact of ODN. By Zahra Hajilou from Royan Institute and colleagues in October, HCC awareness month. https://lnkd.in/dp8iGMHm

🔸Key Speaker of CGC2024 🔹Dr .Massoud Vosough Massoud Vosough is medical professional with a diverse background in the regenerative medicine. After graduating from Tehran University of Medical Sciences in general medicine, he continued his studies and specialized in medical biotechnology, pursuing a doctorate at the Pasteur Institute of Iran. His research focus culminated in thesis on the “mass production of liver cells in a bioreactor, utilizing both embryonic and induced stem cells”, which was conducted at Royan Institute. After successfully defending his thesis, Massoud passed two consecutive postdoctoral programs at Karolinska Institute in Sweden, where he worked under the guidance of Professor Stefan Strom. During this period, he contributed to the HUMAN project in the European Union and various other projects in the realm of regenerative medicine. Presently, Massoud is the head of the Regenerative Medicine Department at Royan Institute. 🌐 WWW.ICGCS.COM 🔺 T.me/icgcs           🔺 instagram.com/icgcs

So excited to attend the first symposium "Regenerative Medicine and Advanced Technologies" in Zanjan University of Medical Sciences in collaboration with Royan Institute! The latest advancements in this field will be presented in the symposium on October 17, 2024. Massoud Vosough, MD, Ph.D Marzieh Ebrahimi Sara Pahlavan Mohammad Hossein Ghanian Samad Nadri, and Dr. Hosein Ranjbaran Virtual link is here! https://lnkd.in/dsut7iFa

Clinical trial led by Johns Hopkins Kimmel Cancer Center investigators shows that adding a personalized anti-tumor vaccine to PD-1 inhibitor therapy may improve patient outcomes in HCC patients. Follow us at HCC_Awareness_Campaign https://lnkd.in/dhthZDYR

Only in three years, the American Society of Clinical Oncology recently updated Clinical Practice Guidelines for patients with advanced liver cancer. The updated guidance includes data from randomized controlled clinical trials published through October 2023. After a decade of only "sorafenib", we have five positive front-line regimens and other approved therapies.

CAR-T Cell Therapy Shows Promise for Liver Cancer In a groundbreaking first human trial, the next-generation CAR-T therapy, has shown remarkable potential in treating advanced liver cancer. Six out of eight patients receiving the highest dose experienced significant tumor shrinkage. This innovative therapy targets the GPC3 antigen found in liver tumors, offering new hope for patients with hepatocellular carcinoma. Developed by AstraZeneca and AbelZeta, C-CAR031's success marks a major advancement in using CAR-T therapy for solid tumors. https://lnkd.in/gUkDvDyG

🌎 October is Cancer Awareness Month. ✔️ Read the updated articles by following this page.